Stocks · News reference
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
JP Morgan analyst Jessica Fye reinstates Emergent BioSolutions (NYSE:EBS) with a Underweight.